Skin-related Quality of Life in Patients with Lung Cancer Taking Oral Targeted Agents: A Single-Center, Cross-Sectional Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to investigate the level of the relationship between skin toxicities and skin-related quality of life (QoL) in patients with lung cancer taking oral targeted agents. Methods: This cross-sectional study surveyed 152 lung cancer patients receiving oral targeted agents. The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PROCTCAE) was used to assess skin toxicity. The Dermatology Life Quality Index (DLQI) was used to evaluate skin-related QoL. Collected data were analyzed with independent t-test, one-way ANOVA, and Pearson correlation using the SPSS 27.0 statistical analysis software for Windows. Results: Skin toxicity was the highest among patients who reported skin dryness 2.07±1.20, followed by itching 1.91±1.25, rash 1.48±1.32, skin darkening 1.39±1.16, hives 1.38±1.25, acne 1.37±1.36, nail (finger or toe) ulceration 1.34±1.34, nail ridging 1.20±1.14, sensitivity to sunlight 1.10±1.07, stretch marks 0.95±1.13, hair loss 0.91±1.14 and nail discoloration 0.83±1.07. The subjects' mean skin-related QoL of the participants was 7.29±6.11 out of 30. Skin-related QoL showed a statistically significant positive correlation with skin toxicity. Conclusion: Skin toxicities correlated significantly with poor skin-related QoL. Skin toxicity levels in lung cancer patients receiving oral targeted therapies need to be closely monitored, and strategies to enhance skin-related QoL must be developed.
Abstract
Purpose: This study aimed to investigate the level of the relationship between skin toxicities and skin-related quality of life (QoL) in patients with lung cancer taking oral targeted agents. Methods: This cross-sectional study surveyed 152 lung cancer patients receiving oral targeted agents. The Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PROCTCAE) was used to assess skin toxicity. The Dermatology Life Quality Index (DLQI) was used to evaluate skin-related QoL. Collected data were analyzed with independent t-test, one-way ANOVA, and Pearson correlation using the SPSS 27.0 statistical analysis software for Windows. Results: Skin toxicity was the highest among patients who reported skin dryness 2.07±1.20, followed by itching 1.91±1.25, rash 1.48±1.32, skin darkening 1.39±1.16, hives 1.38±1.25, acne 1.37±1.36, nail (finger or toe) ulceration 1.34±1.34, nail ridging 1.20±1.14, sensitivity to sunlight 1.10±1.07, stretch marks 0.95±1.13, hair loss 0.91±1.14 and nail discoloration 0.83±1.07. The subjects' mean skin-related QoL of the participants was 7.29±6.11 out of 30. Skin-related QoL showed a statistically significant positive correlation with skin toxicity. Conclusion: Skin toxicities correlated significantly with poor skin-related QoL. Skin toxicity levels in lung cancer patients receiving oral targeted therapies need to be closely monitored, and strategies to enhance skin-related QoL must be developed.
참고문헌 (27)
- "National Cancer Information Center"[URL]
- Lee Jae Guk, "Recent Trends of Lung Cancer in Korea", Tuberculosis and Respiratory Diseases, 84(2), pp.89~95 (2021), 대한결핵및호흡기학회[DOI]
- Novello S, "ESMO Guidelines Committee. Metastatic non-small-cell lung cancer:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 27, pp.v1~v27 (2016)
- Li Y, "Mechanism of Lethal Skin Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors and Related Treatment Strategies", Front Oncol, 12, pp.804212~ (2022)
- Feld R, "Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidencebased Care. Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer : a systematic review", J Thorac Oncol, 1, pp.367~376 (2006)
- Kozuki T, "Skin problems and EGFR-tyrosine kinase inhibitor", Jpn J Clin Oncol, 46, pp.291~298 (2016)
- Chan JC, "A correlational study of skin toxicity and quality of life in patients with advanced lung cancer receiving targeted therapy", J Nurs Res, 27, pp.e51~ (2019)
- Tseng LC, "Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer : An observational study", Medicine(Baltimore), 99, pp.e20510~ (2020)
- Rosen AC, "Impact of dermatologic adverse events on quality of life in 283 cancer patients : a questionnaire study in a dermatology referral clinic", Am J Clin Dermatol, 14, pp.327~333 (2013)
- Chernyshov PV, "The Evolution of Quality of Life Assessment and Use in Dermatology", Dermatology, 235, pp.167~174 (2019)
- "Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE™)"[URL]
- Finlay AY, "Dermatology Life Quality Index(DLQI)--a simple practical measure for routine clinical use", Clin Exp Dermatol, 19, pp.210~216 (1994)
- Mazharinia N, "Dermatology Life Quality Index(DLQI)scores in burn victims after revival", J Burn Care Res, 28, pp.312~317 (2007)
- 이재원, "The Impact of Skin Problems on the Quality of Life in Patients Treated with Anticancer Agents: A Cross-Sectional Study", Cancer Research and Treatment, 50(4), pp.1186~1193 (2018), 대한암학회
- Kandwal M, "Skin diseases in geriatrics and their effect on the quality of life : A hospital-based observational study", J Family Med Prim Care, 9, pp.1453~1458 (2020)
- Farage MA, "Assessing quality of life in older adult patients with skin disorders", Glob J Health Sci, 4, pp.119~131 (2012)
- Osio A, "Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors", Br J Dermatol, 161, pp.515~521 (2009)
- 임효남, "웰에이징을 위한 노인의 건강증진행위와 교육요구도 조사", 한국산학기술학회논문지, 23(6), pp.333~342 (2022), 한국산학기술학회[DOI]
- Guggina LM, "EGFR inhibitors and cutaneous complications:A practical approach to management", Oncol Ther, 5, pp.135~148 (2017)
- Grande R, "Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study", Support Care Cancer, 21, pp.1691~1695 (2013)
- Pinto C, "Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: Update of the Italian expert recommendations", Am J Clin Oncol, 39, pp.407~415 (2016)
- Hofheinz RD, "Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors", Oncologist, 21, pp.1483~1491 (2016)
- Chan JC, "A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy", J Nurs Res, 27, pp.e51~ (2019)
- Hirayama K, "Relationships between quality of life and skin toxicities of epidermal growth factor receptor inhibitors in cancer patients: A literature review", Jpn J Nurs Sci, 17, pp.e12321~ (2020)
- Basch E, "Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)", J Natl Cancer Inst, 106 (2014)
- Cho J, "Linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Korean", J Glob Oncol, 5, pp.1~10 (2019)
- "Guidebook on considerations when applying PRO-CTCAE to clinical trials"[URL]